Prescription Drugs, Pharmaceutical

French Autorité de la Concurrence Fines Sanofi €40.6 Million for Denigrating Competing Generics"

by Simon Baxter, Frederic Depoortere, Ingrid Vandenborre, James Venit | Skadden, Arps, Slate, Meagher & Flom LLP on 5/21/2013

On May 14, 2013, the French Autorité de la Concurrence (Autorité) issued a decision imposing a fine of €40.6 million on French company Sanofi-Aventis France (Sanofi) for an abuse of dominance in the market for the...more

Are Your Prescription Drugs Safe?

by Thorsnes Bartolotta McGuire LLP on 5/21/2013

Millions of people rely on daily medication — from over-the-counter medications to treat minor sickness to sophisticated prescription drugs and vaccines to prevent or cure illness. We depend on drugs to treat pain, relieve...more

Jury Buys Plaintiff’s Argument That Drug Manufacturer Should Have Distributed Dear Doctor Letter Sooner, Without Prior FDA...

by Ellen Adler, James W. Huston, Joanna Simon | Morrison & Foerster LLP on 5/16/2013

Dear Doctor letters were front and center in the just-tried case of Tietz v. Abbott Laboratories, Inc., et al., No. 12-L-002715. On Thursday, May 9, 2013, a Chicago jury returned a $2.2 million verdict in favor of the...more

China Life Sciences Health Industry Client Briefing – April 2013 (May 15, 2013)

by Vicki Lung, Gordon B. Schatz, Katherine Yang, Amy Yin | Reed Smith on 5/15/2013

Pharmaceuticals, Medical Devices, Health Care & Life Sciences - ..Drugs - Approval of Innovative Drugs and Key Sector Generic Drugs to be Expedited (Shanghai Securities Journal 2013-04-23): Given the...more

Bayer Healthcare Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc. (Fed. Cir. 2013)

by Michael Greenfield | McDonnell Boehnen Hulbert & Berghoff LLP on 4/25/2013

Contraceptives were the subject of the Federal Circuit's recent decision in Bayer Healthcare Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc. But, unfortunately, it's a rather fact-specific case with nothing of prurient...more

Lawsuits Claim SSRIs Can Cause Severe Birth Defects [Video]

by Lawyers.com on 4/22/2013

Millions of patients take selective serotonin reuptake inhibitors (SSRIs) for depression, anxiety and other disorders. One out of 10 people in the United States use antidepressants, making them one of the most widely...more

Insurance Dispute Freezes Avandia Victims’ Fund [Video]

by Lawyers.com on 4/22/2013

Lawyers.com videojournalist Matt H. Mayes from Los Angeles reports that a big pharma and insurance legal dispute was allowed to deprive innocent victims of money that they were entitled to and often desperately needed. ...more

Patent Watch: Bayer Schering Pharma AG v. Watson Pharm., Inc.

by Lawrence M. Sung | BakerHostetler on 4/19/2013

On April 16, 2013, in Bayer Schering Pharma AG v. Watson Pharm., Inc., the U.S. Court of Appeals for the Federal Circuit (Lourie,* Schall, Prost) reversed the district court's summary judgment that U.S. Reissue Patent No....more

Business Litigation Report -- April 2013

by Quinn Emanuel Urquhart & Sullivan, LLP on 4/15/2013

In This Issue: - Firm News: DoJ Star Healthcare Fraud Prosecutor Joins Washington, D.C. Office; and Quinn Emanuel Wins Top Honors at the Inaugural U.S. Benchmark Annual Awards - Main...more

Federal Court Orders FDA to Approve OTC Sales of “Morning-After Pill,” Finds Current Age and Point-of-Sale Restrictions to be...

by Fuerst Ittleman David & Joseph, PL on 4/11/2013

On April 5, 2013, Judge Edward R. Korman of the United States District Court for the Eastern District of New York found that the Secretary of Health and Human Service’s (“HHS”) decision to limit over-the-counter (“OTC”)...more

The First Amendment and Off-Label Promotion: United States v. Caronia

by Quinn Emanuel Urquhart & Sullivan, LLP on 4/11/2013

For years, the U.S. Department of Justice has aggressively pursued and brought charges over “off-label promotions”—the promotion of drugs for uses that have not received FDA approval—by pharmaceutical manufacturers and their...more

Court Report -- April 07, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 4/8/2013

In This Issue: Novartis Pharmaceuticals Corp. et al. v. Noven Pharmaceuticals Inc. et al.; Purdue Pharmaceutical Products L.P. et al. v. Dr. Reddy's Laboratories, Inc. et al.; Taro Pharmaceuticals North America, Inc....more

Grassley Questions Hospital 340B Program Profits

by Ellyn L. Sternfield | Mintz Levin - Health Law on 4/5/2013

In a March 2013 article, I wrote about members of Congress calling for increased oversight of the 340B drug discount program and, in particular, hospital use of 340B drugs. This week, Senator Charles Grassley of Iowa...more

Beware Of Topamax — It Can Be A Dangerous Drug

by Tate Law Group, LLC on 4/2/2013

Topamax (topiramate) was first approved by the United States Food and Drug Administration (FDA) in 1996 as an anti-convulsant for the treatment of seizures. Topamax was widely used to treat epilepsy in children and adults....more

News from Abroad: UK Court of Appeal Upholds Invalidity of Enantiomer Patent

by McDonnell Boehnen Hulbert & Berghoff LLP on 4/1/2013

Originally published in WP Thompson & Co. on April 1, 2013. The "Obvious to Try" Test Is Overused in Assessing Obviousness - The UK Court of Appeal Decision in Novartis AG vs Generics (UK) Ltd (trading as United...more

Virginia Enacts the First State Law Regulating Interchangeable Biosimilar Products

by Vincent Capuano, L. . Norwood Jameson, Alan Klein, Vicki Norton, Siegfried Ruppert | Duane Morris LLP on 3/28/2013

On March 16, 2013, Virginia became the first state to enact legislation regulating a pharmacist’s substitution of an interchangeable biologic drug for a prescribed reference biologic drug. ...more

340B Drug Pricing Program Notices on Group Purchasing Organizations and Medicaid Exclusion File

by Emily J. Cook, David Ivill | McDermott Will & Emery on 3/28/2013

Following the recent release of new Program Notices regarding the Group Purchase Organization (GPO) prohibition and Medicaid Exclusion File, 340B participating entities should review their 340B program policies and procedures...more

Sharing an Umbrella

by MoFo Tech on 3/26/2013

Big Pharma and academia cement big deals in the quest for bigger prizes - With the patents of many highly profitable blockbuster drugs expiring over the course of a few years, the search is on for new drugs to fill...more

Wait a Minute

by Yavitch & Palmer Co., L.P.A. on 3/25/2013

“Wait a minute, Occifer, I have a subscription for that drug” These days it seems like everyone takes a pill for something. Just go to a doctor with an ache or a pain, and walk away with a little pill to cure what...more

Getting Ready For The Physician Payment ‘Sunshine’ Rule

by Kathleen Howard, Joel R. Levin, Charles Mulaney, Jerica L. Peters | Perkins Coie on 3/22/2013

Originally Published in BNA Bloomberg, Medical Devices Law & Industry Report on March 20, 2013. On February 1, 2013, the Centers for Medicare and Medicaid Services (CMS) published the long-awaited final regulations for...more

China Releases New Essential Drug List

by Katherine Wang | Ropes & Gray LLP on 3/22/2013

China’s Ministry of Health released the new essential drug list (the “2012 EDL”) on March 15, 2013, effective as of May 1, 2013. Essential drugs are those which meet basic health care demands in suitable dosage forms with...more

GEN Compiles List of Top Biopharma R&D Spenders

by Donald Zuhn | McDonnell Boehnen Hulbert & Berghoff LLP on 3/21/2013

Earlier this month, Genetic Engineering & Biotechnology News published its list of the top 20 best-selling prescription drugs worldwide for 2012 (see "GEN Compiles List of Top Selling Drugs for 2012"). The biotech...more

Z-Pack: Pfizer Can’t Assume That Science Will Trump A Scare Story

by David Bartlett | LEVICK on 3/18/2013

This week, the U.S. Food and Drug Administration (FDA) issued a warning that Pfizer’s popular Z-pack antibiotic (also known as Zithromax or Zmax) may cause sudden death in some patients with preexisting heart conditions....more

Two New Developments in First Amendment Challenges to Off-Label Promotion: What's Next?

by King & Spalding on 3/14/2013

Following the Second Circuit’s marquee First Amendment ruling in the Caronia case, two recent developments demonstrate a shift in the battleground for First Amendment challenges to the prohibition on off-label promotion under...more

Appeals Court Rejects Drug Company Executive’s First Amendment Defense and Upholds Wire Fraud Conviction

by King & Spalding on 3/14/2013

A three-judge panel of the U.S. Court of Appeals for the Ninth Circuit, in a recent unpublished opinion, upheld the conviction and sentencing of former InterMune, Inc. executive Scott Harkonen for wire fraud. In 2009, a jury...more

Home

Legal News

Find a Lawyer

Browse Subjects

Subscribe

Pro Services

For Reporters

Prescription Drugs › Pharmaceutical

French Autorité de la Concurrence Fines Sanofi €40.6 Million for Denigrating Competing Generics"

Are Your Prescription Drugs Safe?

Jury Buys Plaintiff’s Argument That Drug Manufacturer Should Have Distributed Dear Doctor Letter Sooner, Without Prior FDA...

China Life Sciences Health Industry Client Briefing – April 2013 (May 15, 2013)

Bayer Healthcare Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc. (Fed. Cir. 2013)

Lawsuits Claim SSRIs Can Cause Severe Birth Defects [Video]

Insurance Dispute Freezes Avandia Victims’ Fund [Video]

Patent Watch: Bayer Schering Pharma AG v. Watson Pharm., Inc.

Business Litigation Report -- April 2013

Federal Court Orders FDA to Approve OTC Sales of “Morning-After Pill,” Finds Current Age and Point-of-Sale Restrictions to be...

The First Amendment and Off-Label Promotion: United States v. Caronia

Court Report -- April 07, 2013

Grassley Questions Hospital 340B Program Profits

Beware Of Topamax — It Can Be A Dangerous Drug

News from Abroad: UK Court of Appeal Upholds Invalidity of Enantiomer Patent

Virginia Enacts the First State Law Regulating Interchangeable Biosimilar Products

340B Drug Pricing Program Notices on Group Purchasing Organizations and Medicaid Exclusion File

Sharing an Umbrella

Wait a Minute

Getting Ready For The Physician Payment ‘Sunshine’ Rule

China Releases New Essential Drug List

GEN Compiles List of Top Biopharma R&D Spenders

Z-Pack: Pfizer Can’t Assume That Science Will Trump A Scare Story

Two New Developments in First Amendment Challenges to Off-Label Promotion: What's Next?

Appeals Court Rejects Drug Company Executive’s First Amendment Defense and Upholds Wire Fraud Conviction

Lawsuits Claim SSRIs Can Cause Severe Birth Defects [Video]

Insurance Dispute Freezes Avandia Victims’ Fund [Video]

Expand Your Reach